Drug recall · August 22, 2018
Valsartan 160 mg Tablets recall
Why: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Valsartan 160 mg Tablets, HDPE 90 cc bottles in cardboard trays, Rx Only, RemedyRepack, Inc., 625 Kolter Drive, Suite 4, Indiana, PA 15701, NDC: 61786-0792-19
- Lots / codes
Lot # B0335344-081717, exp. date 08/2018 Lot # B0363364-110917, exp. date 11/2018 Lot # B0391225-012218, exp. date 01/2019 Lot # B0408458-030618, exp. date 03/2019 Lot # B0384871-010318, exp. date 01/2019 Lot # B0436862-051518, exp. date 05/2019
- Quantity
- 21 bottles of 90 = 1890 tablets
- Company
- RemedyRepack Inc., Indiana, PA
- Distribution
- Product was distributed to three customers in FL and VA.
- Initiated
- August 10, 2018 · Voluntary: Firm initiated
- Classified
- August 16, 2018
- Reported
- August 22, 2018
- Ended
- October 12, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Valsartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.